Pharmacokinetic profile of a new 3-azinomethyl rifamycin (SPA-S-565) in volunteers as compared with conventional rifampicin

International Journal of Clinical Pharmacology Research

Volumn 18, Issue 3, 1998, Pages 137-143

  Kelkar, M S ^a   Saraf, A P ^a   Bakhle, D S ^b   Nazare, V ^a   Ajay, S ^b   Hegde, S ^b   Lal, H M ^b   Cooverji, N D ^b   Bruzzese, T ^c  

^a SIR J J GROUP OF HOSPITALS   (India)

^b GlaxoSmithKline Pharmaceuticals Ltd   (India)

^c Società Prodotti Antibiotici   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3 [(1 DIETHYLAMINOETHYLIDENE)AZINOMETHYL]RIFAMYCIN SV; ALKALINE PHOSPHATASE; AMYLASE; GAMMA GLUTAMYLTRANSFERASE; RIFAMPICIN;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TOLERANCE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; ALKALINE PHOSPHATASE; AMYLASES; ANALYSIS OF VARIANCE; ANTI-INFECTIVE AGENTS; ANTIBIOTICS, ANTITUBERCULAR; AREA UNDER CURVE; CROSS-OVER STUDIES; GAMMA-GLUTAMYLTRANSFERASE; HALF-LIFE; HUMANS; MALE; RIFAMPIN; RIFAMYCINS;

EID: 0031772667     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Bruzzese T., Cedro A., Dell'Acqua E., Di Nardo A., Goi A. New long-acting 3-azinomethyl rifamycins. II Farmaco Ed. Sc., 41, No. 3, 196, 1986.
2. Simonetti N., Bruzzese T., Strippoli V. "In vitro" and "in vivo" antibacterial activity of SPA-S-565, a new rifamycin derivative. IX International Congress of Infectious and Parasitic Diseases. Munich. July 20-26, 1400, 1986.
3. Strippoli V., Bruzzese T., Galli R., Simonetti N. The antibacterial activity of a new 3-azinomethyl-rifamycin. II Farmaco Ed. Sc., 43, No. 7-8, 619, 1988.
4. Zanetti S., Usai D., Nonis A., Fadda G. In-vitro activity of 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis. J. Antimicrob. Chemoth., 37, 357, 1996.
5. Marchese A., Debbia E.A., Schito G.C. In vitro activity of SPA-S-565, a new rifamycin derivative, against clinical isolates of Neisseria Gonorrhoeae. Can. J. Infec. Dis., 6 (Suppl C), 2076. 1995.
6. Hamilton-Miller J.M.T., Bruzzese T., Nonis A., Shah S. Comparative anti-gonococcal activity of S-565, a new rifamycin. Int. J. Antimicrob. Ag., 7, 247, 1996.
7. Gibaldi M., Perrier D. "Pharmacokinetics". Marcel Dekker, New York, 1975.
8. Grizzle J.E. The two period change-over design and its use in clinical trials. Biometrics, 21, 467, 1965.